Results 131 to 140 of about 5,752,243 (395)

Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects

Journal of Hematology & Oncology
Background Reovirus (RV) is an oncolytic virus with natural tropism for cancer cells. We previously showed that RV administration in multiple myeloma (MM) patients was safe, but disease control associated with viral replication in the cancer cells was ...
Ada Alice Dona, Theophilus Tandoh, Lokesh Nigam, Mahmoud Singer, Enrico Caserta, Mariam Murtadha, Yinghui Zhu, Milad Moloudizargari, Preeti Sharma, Ottavio Napolitano, Janet Winchester, Arnab Chowdhury, Alex Pozhitkov, James F. Sanchez, Hawa Vahed, Guido Marcucci, Matt Coffey, Gerard Nuovo, Douglas W. Sborov, Flavia Pichiorri, Craig C Hofmeister   +20 more
doaj   +1 more source

Genomic patterns of progression in smoldering multiple myeloma

Nature Communications, 2018
Smoldering MM (SMM) is a premalignant stage of multiple myeloma (MM). Here the authors perform whole genome sequencing of unique paired samples of SMM progressing to MM, and show that the genomic landscape at the SMM stage is very similar to MM, but ...
Niccolò Bolli, Francesco Maura, Stephane Minvielle, Dominik Gloznik, Raphael Szalat, Anthony Fullam, Inigo Martincorena, Kevin J. Dawson, Mehmet Kemal Samur, Jorge Zamora, Patrick Tarpey, Helen Davies, Mariateresa Fulciniti, Masood A. Shammas, Yu Tzu Tai, Florence Magrangeas, Philippe Moreau, Paolo Corradini, Kenneth Anderson, Ludmil Alexandrov, David C. Wedge, Herve Avet-Loiseau, Peter Campbell, Nikhil Munshi   +23 more
doaj   +1 more source

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.

New England Journal of Medicine, 2019
BACKGROUND Selinexor, a selective inhibitor of nuclear export compound that blocks exportin 1 (XPO1) and forces nuclear accumulation and activation of tumor suppressor proteins, inhibits nuclear factor κB, and reduces oncoprotein messenger RNA ...
A. Chari, D. Vogl, M. Gavriatopoulou, Ajay K. Nooka, Andrew J Yee, Carol A. Huff, P. Moreau, D. Dingli, C. Cole, S. Lonial, M. Dimopoulos, A. Stewart, J. Richter, R. Vij, S. Tuchman, Marc-Steffen Raab, K. Weisel, M. Delforge, Robert F. Cornell, David Kaminetzky, James E Hoffman, Luciano J. Costa, Terri L. Parker, M. Levy, M. Schreder, N. Meuleman, L. Frenzel, M. Mohty, S. Choquet, G. Schiller, R. Comenzo, M. Engelhardt, T. Illmer, P. Vlummens, C. Doyen, T. Facon, L. Karlin, A. Perrot, K. Podar, M. Kauffman, S. Shacham, Lingling Li, Shijie Tang, Carla Picklesimer, J. Saint-Martin, Marsha L. Crochiere, Hua Chang, S. Parekh, Y. Landesman, J. Shah, Paul G Richardson, S. Jagannath   +51 more
semanticscholar   +1 more source

Multiple myeloma presenting with external ear canal mass [PDF]

, 2017
The manifestations of multiple myeloma are protean and related to bony osteolytic lesions, and to medullar and renal insufficiency. We report a patient who presented with otalgia as the inaugural symptom of multiple myeloma.
Abele, R., Allal, A. S., Dulguerov, P., Kurt, A.-M, Montandon, P., Quinodoz, D., Ruefenacht, D.   +6 more
core  

CXCL13 Expression Promotes CAR T Cell Antitumor Activity and Potentiates Response to PD‐1 Blockade

Advanced Science, EarlyView.
This study demonstrates that engineering CAR T cells to express CXCL13 enhances their antitumor efficacy and significantly improves responsiveness to PD‐1 immune checkpoint blockade. CXCL13 promotes T cell persistence, and resistance to early exhaustion via the AKT‐mTOR pathway.
Yang Zhou, Wenli Zhao, Yihan Zhu, Hongyan Liu, Yicheng Sun, Zhengrong Gong, Xuanyi Li, Ziying Liu, Kang Wen, Yicheng Wang, Jie Ren, Ruipei Xiao, Ling Jiang, Yanfeng Hu, Enguang Bi, Xiaoyong Zhang   +15 more
wiley   +1 more source

Mathematical modelling of the pathogenesis of multiple myeloma-induced bone disease [PDF]

, 2014
Multiple myeloma (MM) is the second most common haematological malignancy and results in destructive bone lesions. The interaction between MM cells and the bone microenvironment plays an important role in the development of the tumour cells and MM ...
Blum B, Eriksen EF, Klein B, Lipton A, Mundy GR, Schmitt CP, Shay G   +6 more
core   +1 more source

Inhibition of FOXM1 Synergizes with BH3 Mimetics Venetoclax and Sonrotoclax in Killing Multiple Myeloma Cells through Repressing MYC Pathway

Advanced Science, EarlyView.
Relapsed and refractory multiple myeloma remains a major clinical challenge. This study shows that FOXM1 contributes to resistance against BH3 mimetics in multiple myeloma cells. The FOXM1 inhibitor NB73 enhances the effectiveness of BH3 mimetics by reducing FOXM1 expression and suppressing the MYC pathway.
Zhi Wen, Yidan Wang, Kathryn C. Fox, Adam M. Bissonnette, Luke F. Moat, Terrie E. Kitchner, Kelsey Springstroh, Sung Hoon Kim, Dagna S. Sheerar, Patcharon Tanawattanacharoen, Chady A. Leon, Seth O. Fagbemi, John A. Katzenellenbogen, Scott J. Hebbring, Benita S. Katzenellenbogen, Siegfried Janz, Adedayo A. Onitilo   +16 more
wiley   +1 more source

A DNA-binding Molecule Targeting the Adaptive Hypoxic Response in Multiple Myeloma has Potent Anti-tumor Activity [PDF]

, 2016
Multiple myeloma is incurable and invariably becomes resistant to chemotherapy. Although the mechanisms remain unclear, hypoxic conditions in the bone marrow have been implicated in contributing to multiple myeloma progression, angiogenesis, and ...
Dervan, Peter B., Frost, Patrick J., Mysore, Veena S., Szablowski, Jerzy   +3 more
core   +3 more sources

Harnessing the Biological Responses Induced by Nanomaterials for Enhanced Cancer Therapy

Aggregate, EarlyView.
Nanomaterial (NM)‐induced toxicity can be strategically repurposed for cancer therapy. This review summarizes the mechanism by which NMs selectively activate specific cellular processes to regulate cell fate independently. We also discussed how NMs‐induced biological responses can be leveraged as therapeutic strategies for cancer treatment.
Liting Wang, Hao Fu, Jiangtao Lin, Meng Zhao, Chuanrong Chen, Hongze Liao, Yourong Duan   +6 more
wiley   +1 more source

Early daratumumab therapy improves renal outcomes in newly diagnosed patients with myeloma admitted with kidney injury

Blood Advances
: Cast nephropathy is the most common cause of acute kidney injury (AKI) in patients with multiple myeloma (MM). A prompt reversal of renal injury is paramount for improving clinical outcomes.
E. Bridget Kim, Jack E. Malespini, Matthew Lei, Samuel S. Han, Cole W. Minsky, Andrew R. Branagan, Elizabeth K. O’Donnell, Diana Cirstea, Noopur S. Raje, Andrew J. Yee   +9 more
doaj